Literature DB >> 19893569

Polycomb protein EZH2 regulates E2F1-dependent apoptosis through epigenetically modulating Bim expression.

Z L Wu1, S S Zheng, Z M Li, Y Y Qiao, M Y Aau, Q Yu.   

Abstract

Deregulation of the pRB/E2F pathway, which occurs frequently in human malignancy, is often associated with inappropriate proliferation and/or apoptosis. While the role of E2F1 in apoptosis induction has been well-established, it remains unclear how this pro-apoptotic activity is regulated in cancer. Here we describe EZH2, an oncogenic polycomb histone methyltransferase and an E2F1 target, as an important regulator of E2F1-dependent apoptosis. We show that E2F1 induces EZH2 expression, which in turn antagonizes the induction of E2F1 pro-apoptotic target Bim expression. RNAi-mediated gene depletion of EZH2 enhances E2F1-dependent Bim expression, thereby promoting the pro-apoptotic activity of E2F1. Hence, the concomitant induction of EZH2 and Bim by E2F1 constitutes a fail-safe mechanism to allow tumor cells with aberrant E2F1 activity to evade apoptosis. These findings reveal a novel mechanism by which the apoptotic activity of E2F1 is restrained in human cancer and also provide the first evidence that EZH2 directly regulates apoptotic process in cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19893569     DOI: 10.1038/cdd.2009.162

Source DB:  PubMed          Journal:  Cell Death Differ        ISSN: 1350-9047            Impact factor:   15.828


  52 in total

Review 1.  Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer.

Authors:  Martin Sauvageau; Guy Sauvageau
Journal:  Cell Stem Cell       Date:  2010-09-03       Impact factor: 24.633

2.  VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.

Authors:  Erick Riquelme; Milind Suraokar; Carmen Behrens; Heather Y Lin; Luc Girard; Monique B Nilsson; George Simon; Jing Wang; Kevin R Coombes; J Jack Lee; Waun Ki Hong; John Heymach; John D Minna; Ignacio I Wistuba
Journal:  Clin Cancer Res       Date:  2014-05-21       Impact factor: 12.531

3.  MiR-137 inhibits proliferation and angiogenesis of human glioblastoma cells by targeting EZH2.

Authors:  Jie Sun; Guodong Zheng; Zhengtao Gu; Zhenhui Guo
Journal:  J Neurooncol       Date:  2015-05-05       Impact factor: 4.130

4.  Polycomb group proteins as epigenetic mediators of neuroprotection in ischemic tolerance.

Authors:  Martha Stapels; Chelsea Piper; Tao Yang; Minghua Li; Cheri Stowell; Zhi-gang Xiong; Julie Saugstad; Roger P Simon; Scott Geromanos; James Langridge; Jing-quan Lan; An Zhou
Journal:  Sci Signal       Date:  2010-03-02       Impact factor: 8.192

Review 5.  Role of EZH2 histone methyltrasferase in melanoma progression and metastasis.

Authors:  Fade Mahmoud; Bradley Shields; Issam Makhoul; Laura F Hutchins; Sara C Shalin; Alan J Tackett
Journal:  Cancer Biol Ther       Date:  2016-04-22       Impact factor: 4.742

6.  EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression.

Authors:  Coralie Drelon; Annabel Berthon; Mickael Mathieu; Bruno Ragazzon; Rork Kuick; Houda Tabbal; Amandine Septier; Stéphanie Rodriguez; Marie Batisse-Lignier; Isabelle Sahut-Barnola; Typhanie Dumontet; Jean-Christophe Pointud; Anne-Marie Lefrançois-Martinez; Silvère Baron; Thomas J Giordano; Jérôme Bertherat; Antoine Martinez; Pierre Val
Journal:  Hum Mol Genet       Date:  2016-05-05       Impact factor: 6.150

7.  Targeting Enhancer of Zeste Homolog 2 as a promising strategy for cancer treatment.

Authors:  Irene Marchesi; Luigi Bagella
Journal:  World J Clin Oncol       Date:  2016-04-10

8.  A novel EZH2 inhibitor induces synthetic lethality and apoptosis in PBRM1-deficient cancer cells.

Authors:  Kejia Huang; Rong Sun; Jiarong Chen; Qianye Yang; Yucheng Wang; Yang Zhang; Kun Xie; Tiantian Zhang; Rui Li; Qi Zhao; Liang Zou; Jian Li
Journal:  Cell Cycle       Date:  2020-02-24       Impact factor: 4.534

9.  Integrative Analysis Reveals the Transcriptional Collaboration between EZH2 and E2F1 in the Regulation of Cancer-Related Gene Expression.

Authors:  Han Xu; Kexin Xu; Housheng H He; Chongzhi Zang; Chen-Hao Chen; Yiwen Chen; Qian Qin; Su Wang; Chenfei Wang; Shengen Hu; Fugen Li; Henry Long; Myles Brown; X Shirley Liu
Journal:  Mol Cancer Res       Date:  2015-12-09       Impact factor: 5.852

Review 10.  EZH2 as a mediator of treatment resistance in melanoma.

Authors:  Jessamy C Tiffen; Stuart J Gallagher; Hsin-Yi Tseng; Fabian V Filipp; Barbara Fazekas de St. Groth; Peter Hersey
Journal:  Pigment Cell Melanoma Res       Date:  2016-05-25       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.